asthma
chronic
obstruct
pulmonari
diseas
copd
complex
multifactori
airway
diseas
associ
signific
morbid
mortal
worldwid
asthma
may
caus
allerg
respons
copd
highli
associ
exposur
cigarett
smoke
cs
howev
diseas
may
exacerb
viral
bacteria
infect
fact
asthma
copd
among
top
devast
diseas
world
caus
infecti
agent
term
loss
life
overal
morbid
mizgerd
despit
import
diseas
featur
distinct
clinic
phenotyp
inadequ
control
inhal
corticosteroid
gc
base
therapi
mainstay
therapi
diseas
identif
new
therapeut
target
therefor
remain
research
prioriti
diseas
intens
research
effort
describ
mani
cell
molecul
associ
either
diseas
aetiolog
diseas
multifactori
diseas
signific
inflammatori
compon
strikingli
mani
proinflammatori
chemokin
cytokin
adhes
molecul
respiratori
mucin
growth
angiogen
factor
induc
via
relnuclear
famili
transcript
factor
review
provid
time
summari
literatur
regard
import
asthma
copd
reflect
variou
form
asthma
copd
includ
stabl
form
exacerb
either
diseas
discuss
rel
role
also
argu
asthma
copd
inflammatori
diseas
target
inflammatori
pathway
via
inhibit
realist
logic
strategi
futur
therapeut
intervent
also
discuss
drug
target
may
distinct
advantag
inhal
gc
least
phenotyp
asthma
copd
asthma
chronic
obstruct
pulmonari
diseas
inflammatori
airway
diseas
asthma
defin
variabl
airway
obstruct
usual
accompani
airway
hyperreact
ahr
defin
featur
asthma
includ
bronchoconstrict
due
contract
hypertrophi
airway
smooth
muscl
asm
inflamm
within
airway
process
lead
decreas
lung
function
measur
either
chang
peak
expiratori
flow
pef
time
decreas
forc
expiratori
volum
fev
follow
provoc
histamin
symptom
often
includ
dyspnoea
wheez
tighten
chest
case
immedi
effect
lung
function
revers
short
act
agonist
asthma
accept
heterogen
complex
disord
review
see
wenzel
normal
present
chronic
stabl
diseas
acut
exacerb
often
follow
acut
viral
bacteri
infect
lower
airway
exposur
allergen
result
allerg
cascad
also
caus
asthma
may
work
addit
synergist
manner
exposur
pollut
spannhak
et
al
chauhan
et
al
acut
respiratori
infect
green
et
al
asthma
associ
earli
onset
life
affect
approxim
popul
increas
incid
develop
world
asher
et
al
asthma
may
caus
sever
morbid
even
mortal
due
exacerb
asthma
huge
burden
healthcar
cost
world
wide
uk
cost
asthma
exacerb
fold
higher
per
patient
compar
stabl
asthma
hoskin
et
al
raw
term
annual
cost
asthma
term
gp
consult
emerg
room
admiss
sick
leav
school
absente
treatment
order
billion
gbp
much
known
regard
cell
molecul
contribut
asthma
allerg
cascad
focal
point
research
interest
decad
upon
allergen
exposur
mast
cell
within
airway
sensitis
allergen
specif
ige
trigger
releas
number
preform
mediat
packag
granul
granul
contain
histamin
act
asm
caus
immedi
bronchoconstrict
airway
observ
asthma
mast
cell
synthesis
prostaglandin
leukotrien
kinin
contribut
bronchoconstrict
also
sourc
cytokin
serv
increas
class
switch
ige
b
cell
augment
product
variou
chemokin
epitheli
asm
cell
also
highli
associ
airway
hyperreact
anim
model
asthma
leigh
et
al
yang
et
al
mast
cell
also
produc
variou
chemokin
attract
inflammatori
neutrophil
lymphocyt
eosinophil
airway
lymphocyt
sourc
cytokin
includ
essenti
eosinophil
differenti
bone
marrow
review
see
renauld
recruit
variou
cell
type
especi
cell
thought
contribut
late
asthmat
respons
lar
featur
bronchoconstrict
ahr
sever
asthma
increas
asm
prolifer
fibroblast
differenti
may
contribut
airway
remodel
caus
long
term
limit
lung
function
via
increas
basement
membran
thick
angiogenesi
respiratori
viral
infect
notabl
human
rhinovirus
rv
respiratori
syncyti
viru
rsv
coronavirus
influenza
virus
johnston
et
al
johnston
et
al
freymuth
et
al
rake
et
al
respons
major
asthma
exacerb
atyp
bacteria
mycoplasma
pneumonia
chlamydiophila
pneumonia
also
associ
asthma
exacerb
thumerel
et
al
viral
bacteri
infect
caus
upregul
plethora
proinflammatori
molecul
depend
manner
includ
neutrophil
chemokin
johnston
et
al
zhu
et
al
carter
et
al
pizzichini
et
al
cheon
et
al
donning
et
al
edward
et
al
cell
chemokin
spurrel
et
al
thoma
et
al
rudd
et
al
veckman
et
al
papadopoulo
et
al
addit
variou
cytokin
growth
factor
induc
includ
dallair
et
al
oliv
et
al
edward
et
al
gmcsf
kim
et
al
funkhous
et
al
fibroblast
growth
factor
fgf
vascular
endotheli
growth
factor
vegf
volonaki
et
al
adhes
molecul
papi
johnston
b
murdoch
et
al
respiratori
mucin
includ
et
al
inou
et
al
inou
et
al
also
produc
macrophag
possibl
recognit
viral
bacteri
product
includ
singl
strand
rna
ssrna
doubl
strand
rna
dsrna
lipopolysaccharid
lp
produc
liu
et
al
oliv
et
al
highli
inflammatori
cytokin
serv
maintain
proinflammatori
environ
within
airway
induc
neutrophil
cell
attract
chemokin
viral
induc
asthma
exacerb
asthmat
individu
therefor
cellular
hallmark
one
would
expect
product
mediat
commonli
featur
increas
level
airway
eosinophil
neutrophil
lymphocyt
fraenkel
et
al
grunberg
et
al
pizzichini
et
al
messag
et
al
experiment
human
mous
model
rhinoviru
induc
asthma
exacerb
recent
develop
bartlett
et
al
messag
et
al
newcomb
et
al
regard
treatment
gc
base
therapi
wide
use
therapi
effect
treat
stabl
asthma
less
effect
treat
exacerb
pauwel
et
al
fitzgerald
et
al
allerg
respons
intens
focu
therapeut
intervent
culmin
clinic
trial
use
ige
therapeut
target
antiig
therapi
appear
partial
effect
bousquet
et
al
holgat
et
al
particularli
sever
asthma
outcom
trial
solubl
receptor
humanis
monoclon
antibodi
howev
disappoint
borish
et
al
lecki
et
al
borish
et
al
kip
et
al
obyrn
et
al
recent
clinic
research
program
focus
antibodi
solubl
receptor
therapi
howarth
et
al
berri
et
al
erin
et
al
morjaria
et
al
highlight
import
inflamm
well
respons
asthma
copd
defin
diseas
state
character
chronic
airflow
limit
fulli
revers
ersat
copd
guidelin
airflow
limit
usual
progress
associ
abnorm
inflammatori
respons
follow
rang
differ
stimuli
includ
cs
pollut
pulmonari
viral
bacteri
infect
clinic
characterist
cough
short
breath
sputum
product
reflect
underli
patholog
chang
mucu
hypersecret
cillari
dysfunct
lead
collaps
damag
small
airway
produc
airflow
limit
ga
trap
characterist
obstruct
pictur
spirometri
aetiolog
copd
certainli
associ
smoke
phenotyp
observ
copd
variabl
complex
like
result
variou
genet
environment
factor
copd
associ
onset
later
life
incid
increas
age
popul
affect
adult
fourth
lead
caus
death
worldwid
major
caus
death
still
rise
pauwel
rabe
predict
increas
preval
copd
third
lead
caus
death
worldwid
murray
lopez
stabl
copd
punctuat
exacerb
associ
infect
bacteria
virus
ball
seemung
et
al
papi
et
al
noncapsul
bacteria
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
frequent
isol
bacteria
stabl
copd
exacerb
monso
et
al
virus
detect
least
copd
exacerb
commonli
includ
rv
rsv
seemung
et
al
exacerb
major
caus
morbid
mortal
copd
exacerb
result
faster
declin
lung
function
donaldson
et
al
number
sever
increas
worsen
diseas
donaldson
et
al
associ
mortal
rate
hospitalis
patient
price
et
al
recent
much
learnt
regard
mechan
cs
pulmonari
infect
contribut
copd
stabl
copd
gener
associ
increas
airway
lymphocyt
macrophag
neutrophilia
saetta
et
saetta
et
qiu
et
al
baraldo
et
al
patient
eosinophil
rutger
et
al
copd
cs
also
highli
associ
reactiv
oxygen
measur
analysi
montuschi
et
al
reactiv
oxygen
believ
central
copd
induc
lung
damag
henc
initi
inflamm
exacerb
cellular
infiltr
may
variabl
also
demonstr
increas
neutrophil
chemokin
qiu
et
al
copd
exacerb
also
relat
increas
system
inflammatori
molecul
includ
creactiv
protein
gan
et
al
recent
small
pilot
studi
demonstr
experiment
rv
challeng
feasibl
copd
patient
induc
chang
typic
experienc
exacerb
copd
mallia
et
al
inhal
long
act
b
agonist
laba
short
act
b
agonist
use
symptomat
treatment
copd
anticholinerg
also
administ
b
agonist
anticholinerg
therapi
act
mainli
induc
bronchodil
therebi
reduc
dyspnoea
may
also
reduc
exacerb
frequenc
use
inhal
gc
copd
remain
controversi
inhal
gc
use
recommend
moderatesever
copd
rather
mild
copd
recent
larg
clinic
trial
shown
improv
lung
function
exacerb
frequenc
individu
receiv
combin
inhal
gc
laba
treatment
versu
placebo
oral
gc
therapi
also
recommend
treatment
copd
exacerb
updat
current
treatment
regim
copd
provid
global
strategi
diagnosi
manag
prevent
copd
rabe
et
al
transcript
factor
express
numer
cell
type
play
key
role
express
mani
proinflammatori
gene
lead
synthesi
cytokin
adhes
molecul
chemokin
growth
factor
enzym
review
baldwin
rel
famili
member
believ
play
central
role
varieti
acut
chronic
inflammatori
diseas
reason
signal
pathway
focu
extens
research
last
year
activ
respons
number
stimuli
includ
physic
chemic
stress
lp
dsrna
ssrna
b
cell
mitogen
proinflammatori
cytokin
rothwarf
karin
karin
lin
li
verma
karin
et
al
induc
gene
express
control
complex
seri
enzymat
signal
event
multipl
level
overview
activ
cascad
depict
fig
rel
famili
member
share
ntermin
rel
homolog
domain
rhd
mediat
dimeris
nuclear
transloc
bind
specif
site
within
promot
affect
gene
consensu
site
decamer
sequenc
howev
extens
variat
exist
mammal
five
known
member
rel
famili
precursor
rel
precursor
crel
rel
b
subunit
ubiquit
express
wherea
three
gener
restrict
specif
differenti
cell
type
review
siebenlist
et
al
rest
cell
major
bound
inhibitori
protein
mask
nuclear
localis
sequenc
nl
hold
complex
cytoplasm
number
differ
protein
gener
believ
differ
isoform
associ
particular
rel
protein
dimer
bound
via
rhd
exampl
associ
crel
wherea
bind
crel
hetero
homodim
upon
appropri
stimul
protein
phosphoryl
ubiquin
subsequ
proteasomemedi
degrad
isoform
phosphoryl
stimulu
specif
exampl
phosphoryl
certain
stimuli
includ
lp
wherea
phosphoryl
trigger
activ
level
control
also
thought
impact
cell
type
specif
kinet
respons
turn
influenc
durat
transcript
phosphoryl
activ
rel
protein
occur
via
classic
canon
altern
pathway
classic
pathway
critic
phosphoryl
protein
perform
kinas
ikk
complex
consist
least
three
subunit
two
catalyt
subunit
regulatori
subunit
essenti
modul
nemo
scheidereit
karin
courtoi
et
al
two
catalyt
subunit
fold
activ
phosphoryl
mercurio
et
al
classic
pathway
shown
import
activ
two
kinas
distinct
rather
overlap
function
li
et
al
li
et
al
takeda
et
al
classic
pathway
includ
signal
famili
member
intracellular
pattern
recognit
receptor
includ
retino
acid
induc
gene
rigi
melanoma
differenti
associ
protein
kinas
r
pkr
ligat
tcell
receptor
tcr
signal
tnfr
also
exampl
classic
pathway
review
hacker
karin
fig
altern
pathway
activ
mediat
ligand
receptor
activ
ligand
rankl
dejardin
et
al
novack
et
al
shown
fig
pathway
involv
phosphoryl
process
precursor
nuclear
transloc
heterodim
rel
b
senftleben
et
al
pathway
believ
play
key
role
secondari
lymphoid
organogenesi
adapt
immun
review
lawrenc
bebien
pathway
control
post
translat
modif
includ
modul
interact
rel
protein
signal
pathway
lead
activ
canon
pathway
includ
receptor
lead
irak
activ
phosphoryl
intracellular
viral
receptor
includ
rna
helicas
pkr
activ
tcr
activ
pathway
lead
activ
tnfr
activ
signal
via
tradd
activ
altern
pathway
induc
activ
rankl
lead
activ
nik
compon
transcript
machineri
alter
kinet
nucleu
phosphoryl
statu
influenc
activ
exampl
phosphoryl
may
enhanc
transcript
activ
howev
phosphoryl
reduc
process
naumann
also
associ
transcript
protein
histon
acetyltransferas
hat
histon
deacetylas
hdac
review
ito
et
al
similarli
acetyl
rel
protein
increas
time
locat
nucleu
chen
et
al
furthermor
recent
data
would
suggest
two
modif
step
occur
stepwis
manner
phosphoryl
rela
requir
prior
enhanc
acetyl
rel
improv
transcript
activ
chen
et
al
henc
pathway
repres
well
studi
signal
transduct
pathway
relev
mani
human
diseas
next
part
articl
focu
knowledg
appli
gener
new
therapi
asthma
copd
nuclear
asthma
chronic
obstruct
pulmonari
diseas
evid
express
level
diseas
tissu
model
use
gene
defici
mice
vitro
assay
sever
line
evid
indic
enhanc
pathway
activ
asthmat
tissu
peripher
blood
mononuclear
cell
pbmc
adult
uncontrol
sever
moder
asthmat
higher
level
protein
express
phosphoryl
protein
level
normal
individu
also
children
protein
abund
phosphoryl
also
higher
moder
asthmat
pbmc
compar
normal
individu
la
grutta
et
al
furthermor
compar
nonasthmat
individu
nuclear
extract
bronchial
biopsi
sputum
cell
hart
et
al
cultur
bronchial
epitheli
cell
zhao
et
al
stabl
untreat
asthmat
greater
level
activ
measur
gel
shift
assay
immunofluoresc
nuclear
protein
small
anim
model
allerg
asthma
use
gene
defici
mice
highlight
import
diseas
pathogenesi
wealth
small
anim
studi
demonstr
role
inflamm
follow
respiratori
viral
bacteri
infect
haeberl
et
al
haeberl
et
al
sadikot
et
al
quinton
et
al
also
appear
import
allerg
respons
ovalbumin
ova
sensitis
challeng
model
total
lung
extract
brownnorway
rat
exhibit
enhanc
activ
lin
et
al
murin
model
bronchial
epithelium
exhibit
robust
rapid
nuclear
transloc
activ
compar
control
poynter
et
al
mice
lack
reduc
eosinophil
respons
aerolis
allergen
effect
shown
due
lack
cell
product
cytokin
eosinophil
growth
factor
da
et
al
also
chemokin
eotaxin
yang
et
al
sinc
play
crucial
role
classic
pathway
consider
interest
studi
develop
way
manipul
kinas
initi
gene
delet
studi
mice
result
liver
degener
led
embryon
lethal
li
et
al
b
limit
overcom
creation
tissu
specif
defici
mice
target
delet
clara
epitheli
cell
bronchial
tissu
broid
et
al
upon
ova
sensitis
challeng
airway
eosinophil
mucu
peribronchiolar
fibrosi
eotaxin
cell
chemokin
tarc
reduc
compar
litterm
control
function
work
demonstr
import
signal
allerg
inflamm
mucu
product
relev
asthma
also
extens
literatur
concern
inhibit
lung
cell
vitro
use
rang
pharmacolog
inhibitor
domin
neg
kinas
mutant
nasuhara
et
al
li
et
al
catley
et
al
constitut
express
protein
sequest
cytoplasm
thoma
et
al
ciesielski
et
al
studi
underscor
import
signal
gener
proinflammatori
cytokin
chemokin
adhes
molecul
nasuhara
et
al
catley
et
al
birrel
et
al
catley
et
al
catley
et
al
dajani
et
al
newton
et
al
also
outcom
viral
zhu
et
al
kim
et
al
edward
et
al
edward
et
al
bacteri
infect
krull
et
al
provid
highli
use
test
ground
research
develop
improv
therapeut
asthma
much
research
effort
develop
treatment
focus
inhibit
inflamm
associ
copd
increas
marker
pathway
activ
demonstr
airway
sampl
copd
patient
includ
sputum
macrophag
caramori
et
al
exacerb
copd
also
bronchial
biopsi
stabl
copd
patient
di
stefano
et
al
rodent
model
copd
involv
cs
exposur
marwick
et
al
express
cytokin
chapov
et
al
activ
implic
diseas
pathogenesi
shown
express
mous
airway
epitheli
cell
result
increas
inflammatori
mediat
neutrophil
inflamm
reminisc
copd
airway
follow
bacteri
challeng
sadikot
et
al
addit
inhibit
vivo
vitro
reduc
induc
product
one
major
compon
respiratori
mucu
lora
et
al
product
anoth
import
respiratori
mucin
also
shown
depend
follow
rv
infect
vitro
n
bartlett
unpublish
observ
henc
grow
evid
support
role
signal
copd
pathogenesi
vitro
system
also
use
highlight
critic
role
activ
conron
et
al
transfect
alveolar
macrophag
adenoviru
construct
express
defect
nik
protein
inhibit
macrophag
activ
express
monocyt
deriv
macrophag
infect
vitro
rv
produc
depend
manner
sensit
treatment
inhibitor
one
possibl
caveat
inhibit
asthma
copd
suppress
benefici
host
respons
like
asthma
copd
exacerb
viral
bacteri
aetiolog
asthma
recent
data
highlight
import
type
type
iii
crucial
host
defenc
viral
infect
wark
et
al
contoli
et
al
induc
virus
depend
manner
thano
maniati
wathelet
et
al
chu
et
al
osterlund
et
al
target
asthma
copd
may
reduc
harm
proinflammatori
allergen
induc
respons
may
also
reduc
benefici
antivir
respons
issu
requir
clarif
appropri
anim
model
target
viral
induc
asthma
exacerb
appli
human
studi
list
cytokin
chemokin
molecul
regul
depend
manner
associ
asthma
copd
provid
tabl
inhal
oral
gc
remain
effect
treatment
asthma
copd
glucocorticoid
receptor
gr
cytoplasm
steroid
hormon
receptor
undergo
conform
chang
dimeris
upon
ligat
gc
rapid
nuclear
transloc
vitro
studi
show
gr
act
via
rang
differ
mechan
includ
prevent
interact
cisact
site
transcript
factor
structur
protein
requir
transcript
process
broadli
known
transrepress
tuckermann
et
al
tao
et
al
gr
activ
lead
express
phosphatas
prevent
inflammatori
kinas
signal
issa
et
al
via
recruit
hdac
prevent
histon
acetyl
disassoci
chromatin
therefor
bind
given
promot
ito
et
al
ito
et
al
gc
impact
signal
shown
fig
gc
often
use
conjunct
therapi
laba
leukotrien
receptor
antagonist
gc
base
therapi
effect
treatment
stabl
allerg
asthma
less
effect
copd
even
less
exacerb
either
diseas
pauwel
et
al
calverley
et
al
despit
continu
relianc
gc
base
therapi
asthma
copd
major
research
object
find
better
treatment
exacerb
asthma
copd
sever
studi
examin
efficaci
gc
base
therapi
reduc
activ
ex
vivo
materi
mix
result
patient
stabl
asthma
undergo
treatment
budesonid
budesonid
increas
grdna
bind
bronchial
biopsi
reduc
bind
hancox
et
al
support
wilson
et
al
demonstr
reduct
activ
stain
treatment
budesonid
laba
formoterol
wilson
et
al
bronchial
biopsi
budesonid
treat
individu
also
significantli
less
gmcsf
howev
differ
observ
formoterol
treat
sampl
contrast
hart
et
al
studi
bind
stabl
asthmat
bronchial
biopsi
alveolar
macrophag
treatment
fluticason
propion
show
decreas
activ
compar
placebo
administ
control
group
fluticason
effect
howev
reduc
bal
eosinophil
improv
lung
function
hart
et
al
togeth
data
suggest
lung
tissu
gc
incomplet
effect
block
activ
antiinflammatori
activ
gc
may
act
via
mechan
effect
gc
control
mediat
allerg
respons
lymphocyt
also
examin
cell
clone
stabl
asthmat
synthesis
upon
stimul
antitcr
antibodi
treatment
mori
et
al
dexamethason
effect
reduc
synthesi
model
author
also
demonstr
target
gc
action
like
fluticason
salmeterol
also
caus
decreas
level
asthmat
cell
pace
et
al
suggest
may
also
target
gc
action
current
studi
examin
effect
gc
base
therapi
express
follow
asthma
copd
exacerb
clearli
less
effect
stabl
diseas
lack
efficaci
exacerb
remain
poorli
understood
one
theori
exacerb
viral
bacteri
aetiolog
may
involv
distinct
mechan
involv
differ
cell
molecul
stabl
form
either
diseas
vitro
normal
tissu
gc
base
therapi
reduc
inflammatori
mediat
induc
viral
nonvir
stimuli
efficaci
edward
et
al
edward
et
al
argu
also
support
fact
much
underli
inflamm
stabl
nonvir
viral
bacteri
induc
exacerb
involv
research
particularli
asthmat
copd
tissu
test
known
inhibitor
model
asthma
copd
exacerb
requir
care
scrutin
mechan
cisact
site
within
variou
promot
conserv
motif
decoy
oligonucleotid
bind
activ
rel
protein
prevent
bind
nuclear
target
repres
potenti
therapeut
agent
oligonucleotid
dnapeptid
ortholog
shown
proof
concept
vitro
tomita
et
al
mischiati
et
al
romanelli
et
al
studi
variou
anim
model
includ
sepsi
matsuda
et
al
asthma
desmet
et
al
furthermor
decoy
oligonucleotid
cell
cycl
regul
triall
ex
vivo
clinic
trial
treatment
vein
graft
reject
mann
et
al
alexand
et
al
use
ova
challeng
sensitis
mous
model
asthma
desmet
et
al
assess
efficaci
decoy
oligonucleotid
ovalbumin
induc
allerg
airway
inflamm
desmet
et
al
initi
experi
demonstr
target
cell
popul
within
lung
consist
dc
cell
macrophag
granulocyt
locat
bronchial
perivascular
area
lung
interestingli
structur
cell
includ
bronchial
epitheli
cell
transfect
studi
h
post
treatment
mice
treat
decoy
oligonucleotid
exhibit
lower
bal
eosinophil
neutrophil
lymphocyt
macrophag
compar
untreat
ovalbumin
challeng
mice
mice
treat
scrambl
nonspecif
oligonucleotid
differ
also
observ
bal
cytokin
eotaxin
lower
mice
challeng
ovalbumin
treat
decoy
oligonucleotid
treat
anim
also
exhibit
less
ahr
control
group
strongli
suggest
inhibit
directli
affect
lung
function
model
final
pa
stain
lung
section
reveal
lower
level
mucin
protein
ova
challeng
decoy
inflammatori
cytokin
haddad
lymphocyt
macrophag
matur
neutrophil
gener
bone
marrow
funkhous
et
al
cytokin
mori
et
al
cytokin
da
et
al
cytokin
da
et
al
chemokin
neutrophil
chemokin
neutrophil
chemokin
sachs
et
al
neutrophil
chemokin
neutrophil
chemokin
issa
et
al
neutrophil
chemokin
bezzerri
et
al
press
cell
chemokin
berin
et
al
cell
immatur
dc
chemokin
matsukura
et
al
eosinophil
chemokin
yang
et
al
cell
chemokin
thoma
et
al
cell
chemokin
spurrel
et
al
monocyt
chemokin
mucin
respiratori
mucin
kraft
et
al
respiratori
mucin
inou
et
al
respiratori
mucin
li
bobek
receptor
leukocyt
adhes
papi
johnston
leukocyt
adhes
papi
johnston
low
affin
receptor
ige
debnath
et
al
coreceptor
debnath
et
al
ige
allergen
bind
mast
cell
basophil
oomizu
et
al
enzym
covert
arachidon
acid
prostaglandin
steer
et
al
ino
produc
nitric
oxid
proteas
associ
remodel
extracellular
matrix
cell
migrat
rhee
et
al
oligonucleotid
treat
anim
compar
control
anim
ige
level
affect
suggest
compon
allerg
cascad
affect
use
strategi
describ
substanti
data
suggest
inhibit
could
benefici
diseas
modifi
properti
target
repres
grow
area
interest
academ
research
industri
alik
plethora
small
molecul
inhibitor
recent
becom
avail
yet
clinic
trial
use
inhibitor
asthma
copd
howev
sever
inhibitor
use
phase
ii
clinic
trial
disord
notabl
cancer
review
karin
et
al
compound
wide
use
research
particularli
small
anim
model
current
least
eight
small
molecul
inhibitor
avail
efficaci
cell
base
vitro
assay
low
micromolar
rang
list
inhibitor
present
tabl
inhibitor
rigor
test
cell
base
assay
system
show
reliabl
antiinflammatori
activ
use
rang
stimuli
birrel
et
al
ziegelbau
et
al
catley
et
al
issa
et
al
newton
et
al
would
appear
inhibitor
may
possess
comprehens
antiinflammatori
profil
gc
instanc
induc
gcsf
releas
primari
asm
virtual
steroid
resist
wherea
complet
block
two
structur
differ
inhibitor
birrel
et
al
potenti
excit
inflamm
copd
patient
subpopul
asthmat
reportedli
resist
gc
treatment
peroxynitrit
nitrat
hdac
caus
reactiv
oxygen
produc
cs
implic
tabl
avail
small
molecul
inhibitor
compound
assay
refer
proinflammatori
cytokin
express
monocyt
podolin
et
al
data
provid
hideshima
et
al
n
nicotinamid
express
pbmc
wen
et
al
n
proinflammatori
cytokin
express
synovi
fibroblast
kishor
et
al
data
provid
onai
et
al
inhibitor
pathway
small
molecul
peptid
inhibitor
prevent
phosphoryl
proteasom
inhibitor
prevent
process
antisens
sirna
act
mrna
limit
subsequ
protein
express
decoy
oligonucleotid
compet
site
within
promot
affect
gene
prevent
transcript
activ
gc
may
act
bind
activ
famili
member
prevent
associ
site
transrepress
recruit
hdac
prevent
chromatin
disassoci
henc
assess
site
within
affect
gene
caus
steroid
resist
copd
ito
et
al
also
sub
popul
asthmat
believ
reduc
gr
level
gr
transloc
recruit
hdac
reduc
gc
efficaci
adcock
et
al
adcock
et
al
matthew
et
al
henc
distinct
advantag
inhibit
bypass
problem
associ
gc
base
therapi
furthermor
recent
public
suggest
inhibit
may
addit
antiinflammatori
activ
separ
impact
signal
shown
use
inhibitor
structur
differ
inhibitor
domin
neg
tudhop
et
al
mechan
howev
current
unknown
also
cell
permeabl
peptid
specif
disrupt
interact
may
et
al
use
vitro
block
signal
depend
manner
dai
et
al
small
peptid
inhibitor
also
valuabl
tool
highlight
mechan
vitro
perhap
also
therapeut
vivo
small
anim
model
asthma
inhibitor
shown
impact
number
relev
end
point
includ
inflammatori
cytokin
mucu
lar
ahr
fibrosi
birrel
et
al
ziegelbau
et
al
chapov
et
al
exampl
select
inhibitor
reduc
eotaxin
cytokin
induc
ova
rat
model
allergen
sensitis
challeng
recruit
neutrophil
eosinophil
airway
late
respons
allergen
challeng
also
markedli
reduc
follow
administr
birrel
et
al
importantli
result
highlight
abil
reduc
induc
respons
gener
inflamm
follow
allergen
challeng
yet
less
report
impact
inhibitor
similar
model
copd
inhibit
effect
lp
model
copd
ziegelbau
et
al
birrel
et
al
similarli
induc
inflamm
mous
reduc
inhibitor
chapov
et
al
one
might
question
clinic
relev
anim
model
exampl
unlik
inflamm
clinic
copd
lp
induc
inflamm
modul
gc
treatment
anoth
rodent
model
copd
utilis
elastas
stimulu
known
steroid
resist
also
recent
shown
also
resist
inhibitor
birrel
et
al
result
might
expect
inflamm
observ
model
appear
occur
without
obviou
sign
pathway
involv
birrel
et
al
one
may
question
clinic
relev
model
especi
consid
appar
increas
pathway
activ
patient
copd
caramori
et
al
howev
regardless
whether
model
repres
human
copd
appear
demonstr
gc
resist
inflamm
could
interest
explor
yet
report
impact
inhibitor
accept
cs
driven
anim
model
copd
studi
crucial
valid
inhibitor
copd
ubiquitinproteasom
system
up
regul
protein
turnov
eukaryot
cell
central
regul
activ
protein
degrad
up
involv
ubiquitin
conjug
protein
destin
destruct
mediat
enzym
polyubiquin
protein
recognis
proteasom
deubiquin
unfold
destroy
target
protein
review
nalepa
et
al
proteasom
atpdepend
proteolyt
complex
consist
proteolyt
core
particl
proteosom
cap
end
two
regulatori
complex
proteasom
contain
pair
activ
site
distinct
specif
term
chymotrypsinlik
trypsinlik
caspaselik
review
gilmor
herscovitch
sever
class
revers
irrevers
proteasom
inhibitor
target
proteasom
utilis
asthma
copd
research
sever
studi
report
modul
eosinophil
function
block
signal
use
proteasom
inhibitor
eosinophil
secret
varieti
potenti
damag
mediat
respons
proinflammatoryand
microbi
stimuli
depend
manner
rankin
et
al
activ
lactocystinderiv
proteasom
inhibitor
examin
rat
model
ova
induc
pulmonari
eosinophilia
intratrach
dose
allergen
exposur
significantli
reduc
number
eosinophil
sensitis
lung
furthermor
low
dose
similarli
effect
decreas
eosinophil
inflamm
airway
use
combin
gc
budesonid
demonstr
potenti
combin
treatment
regimen
gc
elliott
et
al
member
peptid
aldehyd
class
proteasom
inhibitor
block
chymotrypsinlik
activ
proteasom
complex
palombella
et
al
sever
studi
demonstr
mediat
inhibit
modul
eosinophil
activ
reduc
allerg
inflamm
induc
purifi
human
eosinophil
block
pretreat
addit
inhibit
signal
enabl
induc
eosinophil
apoptosi
rather
induc
product
fujihara
et
al
express
cell
adhes
molecul
integrin
critic
eosinophil
home
site
inflamm
induc
cocultur
bronchial
epitheli
cell
teixeira
et
al
also
initi
express
bronchial
epitheli
cell
via
activ
treatment
reduc
express
eosinophil
cell
follow
cocultur
irrespect
presenc
highlight
role
bronchial
epitheli
cell
mediat
upregul
cell
adhes
molecul
eosinophil
potenti
modul
airway
chemotact
activ
reduc
cell
recruit
via
inhibit
proteasom
also
investig
bronchial
biopsi
atop
asthmat
treat
proteosom
inhibitor
cbzileglu
otbu
alaleucin
exhibit
reduc
cell
chemotact
activ
product
hidi
et
al
tlr
agonist
potent
activ
classic
pathway
inhibit
proteasom
also
reveal
role
stimul
tracheal
contract
one
studi
demonstr
express
smooth
muscl
layer
mous
trachea
increas
contractil
respons
bradykinin
follow
stimul
tlr
agonist
lp
polyic
respons
associ
nuclear
transloc
upregul
kinin
receptor
mrna
could
inhibit
bachar
et
al
role
tlr
signal
activ
asthma
well
studi
much
less
known
cs
induc
tlr
mediat
inflamm
copd
stimul
macrophag
via
lead
activ
product
brightbil
et
al
assess
role
cs
induct
regul
proinflammatori
gene
express
human
monocytederiv
macrophag
treat
cs
vitro
increas
product
observ
respons
depend
activ
associ
phosphoryl
irak
activ
mediat
proteasom
inhibit
prevent
cs
induc
degrad
karimi
et
al
peptid
boron
acid
also
known
dipeptidyl
boron
origin
use
inhibitor
serin
proteas
compris
anoth
class
proteas
inhibitor
block
chymotrypsinlik
site
subunit
core
shown
efficaci
sever
tumour
littl
data
describ
use
treat
airway
inflamm
review
gilmor
herscovitch
larg
clinic
trial
use
proteasom
inhibitor
also
highlight
potenti
side
effect
associ
proteasom
inhibitor
use
clinic
trial
utilis
bortezomib
boron
acid
dipeptid
induc
sever
side
effect
includ
thrombocytopenia
fatigu
peripher
neuropathi
neutropenia
richardson
et
al
thought
side
effect
could
result
express
mani
gene
cellular
process
influenc
proteasom
inhibit
concept
requir
consider
appli
studi
asthma
copd
decoy
oligonucleotid
competit
bind
free
dimer
thu
prevent
interact
cisact
site
within
promot
region
antisens
small
interf
rna
sirna
nucleic
acid
base
agent
target
specif
mrna
reduc
abund
correspond
protein
antisens
technolog
use
stablilis
phosphothion
oligonucleotid
bind
complementari
mrna
thu
block
translat
ova
sensitis
mice
inject
intraven
twice
antisens
oligonucleotid
show
signific
reduct
level
protein
activ
lung
reduct
protein
associ
reduc
airway
inflamm
cell
recruit
ahr
proinflammatori
cytokin
product
bal
ova
specif
ige
serum
choi
et
al
mrna
target
protein
also
reduc
use
sirna
technolog
via
process
rna
interfer
review
see
shrivastava
srivastava
deliv
sirna
transient
silenc
gene
express
direct
sequencespecif
degrad
target
mrna
endogen
rnainduc
silenc
complex
elbashir
et
al
major
report
date
describ
use
sirna
treat
lung
diseas
vivo
target
respiratori
viru
infect
bitko
et
al
demonstr
gener
use
deliv
sirna
airway
vivo
also
studi
use
cultur
airway
epitheli
cell
demonstr
util
sirna
target
reduc
induc
proinflammatori
cytokin
product
primari
epitheli
cell
transfect
sirna
produc
less
respons
howev
depend
cell
undifferenti
time
transfect
platz
et
al
altern
use
transfect
deliv
sirna
lung
use
viral
deliveri
system
anoth
studi
employ
recombin
adenoassoci
viru
express
sirna
use
similar
cellular
model
previou
studi
express
sirna
suppress
secret
cell
pinkenburg
et
al
applic
technolog
vitro
vivo
rel
recent
grow
interest
field
methodolog
associ
design
deliveri
sirna
expand
approach
certain
broaden
rang
therapeut
option
avail
asthma
copd
pathway
central
pathogenesi
asthma
copd
larg
bodi
evid
convincingli
demonstr
clear
role
transcript
factor
signal
kinas
stabl
exacerb
form
either
diseas
data
sum
sever
line
evid
appar
investig
use
diseas
tissu
anim
model
diseas
vitro
cultur
cell
system
role
pathway
clear
methodolog
inhibit
encourag
anim
model
molecul
specif
target
appropri
method
inhibit
human
studi
less
good
evid
small
molecul
inhibit
methodolog
also
use
oligonucleotid
base
methodolog
includ
decoy
oligonucleotid
sirna
care
control
studi
reliabl
anim
model
must
perform
address
complex
issu
form
inhibit
test
human
studi
signal
molecul
repres
best
therapeut
target
perplex
question
knowledg
signal
molecul
expand
research
need
respect
mani
variabl
includ
cell
type
specif
aspect
pathogenesi
inhibit
allerg
versu
non
allerg
inflamm
secret
cytokinechemokin
nonsecret
enzym
adhes
molecul
anoth
import
point
worth
consid
end
point
import
especi
anim
model
inhibit
clearli
affect
rang
differ
end
point
includ
allerg
nonallerg
inflamm
ahr
exist
heterogen
differ
model
truli
salient
point
differenti
target
pathway
differ
cell
type
may
alter
variou
end
point
diseas
outcom
anim
model
like
outcom
may
model
depend
henc
result
differ
model
need
interpret
caution
point
need
thoroughli
consid
futur
studi
go
seriou
contend
therapeut
intervent
human
diseas
wealth
literatur
focus
asthma
copd
also
teas
sever
controversi
regard
suitabl
role
asthma
copd
firstli
consider
role
benefici
host
respons
infecti
agent
secondli
conundrum
known
inhibitor
gc
work
poorli
control
exacerb
asthma
copd
answer
clearli
complex
better
understand
better
defin
diseas
human
system
import
futur
studi
also
particularli
copd
exacerb
diseas
design
use
anim
model
clinic
use
end
point
also
requir
potenti
target
pathway
asthma
copd
therefor
excel
exampl
studi
clinic
pharmacolog
technolog
therapeut
agent
becom
increasingli
avail
opportun
trial
new
treatment
learn
mechan
behind
import
diseas
